What Is the Most Reliable Source for Botulinum Toxin Product Information?

For regulatory questions, the primary source should be the current official product information and regulatory record for the relevant product in the relevant jurisdiction.

This is important because a clinical paper, manufacturer webpage, distributor material or clinic advertisement may provide useful information but does not replace locally approved labeling.

Official product information should be used to verify matters such as:

• exact product identity;

• active substance;

• pharmaceutical form;

• labeled strength;

• manufacturer;

• marketing authorization holder;

• approved indications;

• contraindications;

• warnings and precautions;

• preparation and administration;

• storage conditions; and

• other product-specific regulatory instructions.

The first question should therefore not simply be:

“What does the internet say about this toxin?”

It should be:

“What does the current official information for this exact product say?”

Start With the Exact Product Name

The brand name matters.

“Botulinum toxin type A” describes a pharmacologic class.

It does not identify one specific commercial medicine.

Similarly, the word “Botox” should not be used as a generic regulatory term for every BoNT-A product because BOTOX is a specific brand.

For an evidence-based product record, identify:

Brand name

Active substance

Strength

Dosage form

Registration or authorization number

and, where relevant,

manufacturer and authorization holder.

Why Does the Registration Number Matter?

The registration or marketing authorization number connects the commercial product with a specific regulatory record.

This is useful because products with similar names may exist in:

• different strengths;

• different presentations;

• different markets; or

• different regulatory versions.

A product name alone may therefore be insufficient for precise identification.

For Neuronox in Thailand, the current Thai FDA database lists a 100-unit/vial presentation under registration 1C 1/66(BF) as a lyophilisate for solution for injection.

The database identifies the active substance as botulinum toxin type A and the overseas manufacturer as Medytox Inc., Republic of Korea. [1]

Regulatory information should always be rechecked before publication because authorization records can change.

Manufacturer and Authorization Holder Are Not Necessarily the Same Thing

Several organizations can appear in the regulatory history or supply chain of a medicine.

These may include:

• manufacturer;

• marketing authorization holder;

• importer;

• distributor; and

• local legal entity.

They should not automatically be treated as interchangeable terms.

For example, the current Thai FDA record for the Neuronox 100-U presentation identifies the overseas manufacturer and separately identifies the Thai authorization holder. [1]

This distinction is important for regulatory accuracy and traceability.

What Should Be Checked on the Label?

The exact requirements depend on the jurisdiction, but product identification should generally be checked against authoritative information for details such as:

• brand name;

• active substance;

• labeled strength;

• dosage form;

• batch or lot number;

• expiry date;

• manufacturer;

• registration/authorization information; and

• required storage information.

The label should not be interpreted independently from the approved product information.

A short vial label cannot contain the same level of detail as a full prescribing document.

Why Is the Batch or Lot Number Important?

A batch number identifies a defined production batch.

For biological medicines, batch-level traceability is particularly important.

The European Medicines Agency's good pharmacovigilance guidance states that continuous product and batch traceability is important for biological medicines because product-specific safety or immunogenicity concerns may need to be detected and evaluated over the product lifecycle. [2]

The EMA guidance recommends recording the product name and batch number of an administered biological medicine. [2]

This allows an adverse event or quality concern to be linked more precisely to the actual product exposure.

What Does “Traceability” Mean?

Traceability means being able to identify what product was used and, when appropriate, which batch was administered.

At a practical level, this can include documenting:

• exact product name;

• strength/presentation;

• batch or lot number;

• expiry date;

• date of administration; and

• other information required by local clinical or pharmacovigilance procedures.

Traceability is particularly relevant if there is later:

• an adverse-event investigation;

• a product-quality complaint;

• a recall;

• a batch-specific concern; or

• a pharmacovigilance signal.

Why Is Traceability Especially Important for Biologics?

Biological medicines are produced through complex biological manufacturing processes.

Regulatory pharmacovigilance guidance therefore places particular emphasis on identifying the exact biological product and batch used. [2]

This does not mean every batch is clinically different.

Rather, it means that if a safety or quality issue emerges, sufficiently detailed records are needed to investigate it properly.

Can Packaging Appearance Prove That a Product Is Authentic?

Not by itself.

Packaging can provide useful product-identification information, but visual inspection alone should not be presented as a complete authenticity test.

Packaging may change over time because of:

• regulatory updates;

• artwork revisions;

• market-specific labeling;

• presentation changes; or

• authorized packaging updates.

Conversely, visual similarity alone cannot establish authenticity.

Authenticity questions should be addressed through appropriate authorized supply-chain and regulatory verification processes rather than appearance alone.

Why Should Old Packaging Photos Be Used Carefully?

A photograph from an older publication or website may accurately show a historical presentation but may not represent the current locally authorized package.

This is especially important for a reference website.

If BotoxWiki displays packaging images, the image should be clearly linked to:

• the relevant market;

• presentation;

• source;

• and, when possible, the version or date.

An old photograph should not silently become the current regulatory reference.

What Does the Expiry Date Tell Us?

The expiry date indicates the period during which the product is intended to meet its approved specifications when stored according to the required conditions.

It should not be interpreted separately from storage requirements.

A product that has not been maintained under required storage conditions should not automatically be considered acceptable merely because the printed expiry date has not passed.

Expiry and storage are therefore related but distinct pieces of information.

Why Is Storage Important for Botulinum Toxin Products?

BoNT-A products are biological medicines, and storage conditions are product-specific.

Temperature requirements, handling before reconstitution, conditions after reconstitution and allowable storage periods should be taken from the current product information for the exact presentation.

One BoNT-A product's storage instructions should not automatically be applied to another product.

Likewise, historical instructions should not be copied indefinitely without checking whether the current locally approved information has changed.

What Does the Available Neuronox Information Say About Storage?

Published product comparisons and manufacturer information for Meditoxin/Neuronox have described the lyophilized product as requiring controlled cold storage. [3,4]

However, storage wording can differ by presentation, market and approved product information.

Therefore, for Thailand, the final published storage statement should be taken from the current Thai-approved Neuronox product information for the exact presentation being discussed, rather than copied from another country's webpage.

This distinction is important for regulatory accuracy.

What About Storage After Reconstitution?

Post-reconstitution handling is also product-specific.

Information such as:

• permitted diluent;

• reconstitution procedure;

• storage temperature after reconstitution;

• maximum time before use; and

• microbiological handling requirements

should come directly from the current approved product information.

These instructions should not be reconstructed from another BoNT-A brand or from clinic custom.

Why Should Reconstitution Instructions Not Be Copied Across Brands?

Because BoNT-A products have product-specific labeling, formulations and potency units.

Even when two products are both lyophilized BoNT-A preparations, this does not establish identical:

• diluent instructions;

• final concentrations;

• storage periods;

• handling requirements; or

• approved dosing.

The exact product instructions should be followed.

Approved Indication and Published Research Are Not the Same Thing

This is one of the most important rules when reading product information.

A published clinical trial tells us what researchers studied.

An approved indication tells us what a regulatory authority has authorized for that product in that jurisdiction.

These can overlap, but they are not identical concepts.

A study performed in one population does not automatically create an approved indication in every country.

Likewise, the regulatory evidence package for an approved indication may include more information than one published paper.

Why Does This Matter for Neuronox?

Neuronox has published randomized comparative clinical studies in several settings, including:

• glabellar lines;

• essential blepharospasm;

• cerebral-palsy-associated spastic equinus; and

• post-stroke upper-limb spasticity. [5–8]

These papers are valuable sources for evaluating product-specific clinical evidence.

However, when a website states:

“Neuronox is approved for…”

the statement should be checked against the current locally approved product information rather than inferred from the existence of a paper.

This keeps clinical evidence and regulatory status appropriately separated.

Where Should Contraindications and Warnings Come From?

For product-specific contraindications, warnings and precautions, the current locally approved product information should be the primary regulatory source.

A review article can explain general BoNT-A safety concepts.

It should not replace the official labeling.

This is especially important because wording may differ among products and jurisdictions.

Can Clinical Papers Replace the Package Insert?

No.

Clinical papers and product information answer different questions.

A clinical trial can provide detailed evidence about:

• population;

• intervention;

• comparator;

• dose;

• endpoint;

• efficacy;

• safety; and

• follow-up.

Product information provides the approved regulatory instructions and conditions for use.

A high-quality evidence website needs both.

What Should Be Recorded When Neuronox Is Used?

From a traceability perspective, the most useful product-level information includes the exact product identity and batch information.

Depending on local procedures, records may include:

NEURONOX

strength/presentation

batch or lot number

expiry date

administration date

and other required clinical information.

The principle is simple:

the record should allow the administered biological product to be identified later if necessary.

Does Traceability Say Anything About Efficacy?

No.

Traceability is not an efficacy claim.

Recording the product and batch does not prove that a product is better or worse.

It improves the quality of:

• clinical records;

• pharmacovigilance;

• quality investigations; and

• recall management.

What Is Interesting About Neuronox From an Evidence Perspective?

Neuronox can be identified at several independent evidence levels.

Regulatory identity

The Thai FDA database contains a current product-specific registration record for NEURONOX 100 U/vial. [1]

Product information

The product has specific information regarding identity, formulation, labeling, storage and administration.

Published clinical evidence

Neuronox/Meditoxin has published randomized comparative trials in multiple clinical settings. [5–8]

Traceability

As a biological medicine, its exact product and batch information can be documented in clinical use.

These layers should complement one another rather than be mixed together.

A Practical Checklist for Reading BoNT-A Product Information

Before writing about a product, check:

1. Exact brand name
Do not rely only on the generic class name.

2. Active substance
Confirm what the regulatory record states.

3. Strength and presentation
Do not assume every vial size has identical labeling.

4. Registration/authorization number
Match the product to the correct local regulatory record.

5. Manufacturer
Distinguish manufacturer from distributor or local authorization holder.

6. Approved indications
Use current local labeling.

7. Contraindications and warnings
Use current product-specific information.

8. Reconstitution and administration
Do not copy instructions from another brand.

9. Storage
Check both unreconstituted and, where relevant, reconstituted conditions.

10. Batch and expiry information
Important for traceability.

11. Date/version of the information
Regulatory documents can change.

12. Clinical evidence
Keep research findings separate from regulatory claims.

Frequently Asked Questions

Who manufactures Neuronox?

The current Thai FDA record for NEURONOX 100 U/vial identifies Medytox Inc., Republic of Korea, as the overseas manufacturer. [1]

Is the manufacturer always the same as the Thai authorization holder?

No. These are distinct regulatory roles.

Is a research paper enough to confirm an approved indication?

No. Local approval should be verified from current regulatory information.

Can a packaging photo confirm authenticity?

Not by itself.

Why record the batch number?

It allows more precise traceability for pharmacovigilance, product-quality investigations and recalls.

Can I use another botulinum toxin brand's storage instructions for Neuronox?

No. Storage and handling should follow the current product-specific information.

Bottom Line

For Botulinum Toxin Type A, the most reliable product description begins with the exact locally authorized product, not with assumptions based on the pharmacologic class.

Check:

product name

strength

dosage form

registration

manufacturer

approved labeling

storage

batch

and

expiry information.

For Neuronox, this matters because the product has both an identifiable regulatory record and published product-specific clinical evidence.

The Thai FDA currently lists NEURONOX 100 U/vial as a registered botulinum toxin type A lyophilisate for solution for injection. [1]

At the same time, randomized comparative clinical studies provide a separate evidence layer describing how Neuronox performed in defined clinical protocols. [5–8]

The strongest evidence-based approach is therefore:

Use official product information for regulatory facts.

Use clinical papers for clinical evidence.

Use product and batch documentation for traceability.

Do not replace one source with another.

References

1. Thai Food and Drug Administration. Drug registration database: NEURONOX, botulinum toxin type A, 100 unit/1 vial. Registration 1C 1/66(BF). Regulatory database accessed September 2026.

2. European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Product- or Population-Specific Considerations II — Biological Medicinal Products. Section P.II.A.1.4, Product Traceability.

3. Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Snyder D, Foster K. AbobotulinumtoxinA (Dysport), onabotulinumtoxinA (Botox), and incobotulinumtoxinA (Xeomin) neurotoxin content and potential implications for duration of response in patients. Toxins (Basel). 2018;10(12):535.

4. Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol. 2018. [Product-composition and storage comparison.]

5. Won CH, Lee HM, Lee WS, et al. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072.

6. Yoon JS, Kim JC, Lee SY. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137.

7. Kim K, Shin HI, Kwon BS, et al. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x.

8. Seo HG, Paik NJ, Lee SU, et al. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633.

9. NEURONOX (Botulinum toxin Type A) Thai Product Information. Revised April 3, 2023.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.